Item 8.01. Other Events

On January 29, 2013, Depomed, Inc. ("Depomed") filed a complaint in the United States District Court for the District of New Jersey against Purdue Pharma L.P. and affiliated companies (collectively, "Purdue") for infringement of U.S. Patent Nos. 6,340,475; 6,635,280; and 6,723,340 (collectively, the "Depomed Patents"). The complaint alleges infringement of the Depomed Patents arising from Purdue's commercialization of OxyContin® (oxycodone hydrochloride controlled-release) in the United States.

The Depomed Patents relate to Depomed's Acuform® drug delivery technology. U.S. Patent Nos. 6,340,475 and 6,635,280 will expire in 2016, and U.S. Patent No. 6,723,340 will expire in 2021.